Articles related to LIPID HEALTH

LDL-C reductions were evident by week 4 and sustained through 52 weeks (−55.3% vs 8.7%).

“For persons at low cardiovascular risk, reducing or modifying saturated fat intake has little or no benefit over a period of 5 years.”

“Pelacarsen lowered lipoprotein(a) to less than 50 mg/dL in 98% of participants, but levels rebounded after 16 weeks.”

“The main scenario that prompts me to use apoB is when a patient’s traditional lipid panel values are either normal, or even slightly abnormal, but have discrepancy with the quality/quantity of their other comorbid problems.” — Austin Shuxiao, MD

Triple therapy was linked with slower decline of overall cognition, particularly in semantic and working memory, and showed lower odds of atherosclerosis, reduced AD pathology, and fewer protein buildups.

The article presents evidence suggesting cardiovascular risk may correlate more strongly with inflammatory processes than cholesterol levels, recommending CRP monitoring alongside comprehensive biomarker assessment and lifestyle modifications targeting inflammation reduction through carbohydrate restriction.